Siegfried Ansorge

Summary

Country: Germany

Publications

  1. ncbi Novel aspects of cellular action of dipeptidyl peptidase IV/CD26
    Siegfried Ansorge
    IMTM GmbH, Department ImmunoPharm, Leipziger Str 44, D 39120 Magdeburg, Germany
    Biol Chem 392:153-68. 2011
  2. ncbi Propolis and some of its constituents down-regulate DNA synthesis and inflammatory cytokine production but induce TGF-beta1 production of human immune cells
    Siegfried Ansorge
    Institute of Medical Technology Magdeburg, Germany
    Z Naturforsch C 58:580-9. 2003
  3. ncbi Dipeptidyl peptidase IV (DP IV, CD26) and aminopeptidase N (APN, CD13) as regulators of T cell function and targets of immunotherapy in CNS inflammation
    Dirk Reinhold
    Institute of Immunology, Otto von Guericke University Magdeburg, Leipziger Str 44, 39120 Magdeburg, Germany
    Int Immunopharmacol 6:1935-42. 2006
  4. ncbi Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and aminopeptidase N (APN) families in immune functions
    Siegfried Ansorge
    IMTM GmbH, Magdeburg, Germany
    Clin Chem Lab Med 47:253-61. 2009
  5. ncbi Role of dipeptidyl peptidase IV (DP IV)-like enzymes in T lymphocyte activation: investigations in DP IV/CD26-knockout mice
    Dirk Reinhold
    Institute of Molecular and Clinical Immunology, Otto von Guericke University Magdeburg, Magdeburg, Germany
    Clin Chem Lab Med 47:268-74. 2009
  6. ncbi Inhibitors of dipeptidyl peptidase IV and aminopeptidase N target major pathogenetic steps in acne initiation
    Anja Thielitz
    Department of Dermatology and Venereology, Otto von Guericke University Magdeburg, Magdeburg, Germany
    J Invest Dermatol 127:1042-51. 2007
  7. ncbi Inhibition of alanyl-aminopeptidase on CD4+CD25+ regulatory T-cells enhances expression of FoxP3 and TGF-beta1 and ameliorates acute colitis in mice
    Ute Bank
    IMTM GmbH, D 39120 Magdeburg, Germany
    Int J Mol Med 20:483-92. 2007
  8. ncbi Triggering endogenous immunosuppressive mechanisms by combined targeting of Dipeptidyl peptidase IV (DPIV/CD26) and Aminopeptidase N (APN/ CD13)--a novel approach for the treatment of inflammatory bowel disease
    Ute Bank
    IMTM GmbH, Leipziger Str 44, 39120 Magdeburg, Germany
    Int Immunopharmacol 6:1925-34. 2006
  9. ncbi Synergistic action of DPIV and APN in the regulation of T cell function
    Uwe Lendeckel
    Institute of Experimental Internal Medicine, Otto von Guericke University Magdeburg, Leipziger Strasse 44, D 39120 Magdeburg, Germany
    Adv Exp Med Biol 524:123-31. 2003
  10. ncbi Dual inhibition of dipeptidyl peptidase IV and aminopeptidase N suppresses inflammatory immune responses
    Dirk Reinhold
    Institute of Immunology, Otto von Guericke University Magdeburg, Leipziger Str 44, 39120 Magdeburg, Germany
    Ann N Y Acad Sci 1110:402-9. 2007

Collaborators

Detail Information

Publications41

  1. ncbi Novel aspects of cellular action of dipeptidyl peptidase IV/CD26
    Siegfried Ansorge
    IMTM GmbH, Department ImmunoPharm, Leipziger Str 44, D 39120 Magdeburg, Germany
    Biol Chem 392:153-68. 2011
    ..This finding suggests a crucial role of the immunosuppressive cytokine NPY in the function of DPIV in growth regulation...
  2. ncbi Propolis and some of its constituents down-regulate DNA synthesis and inflammatory cytokine production but induce TGF-beta1 production of human immune cells
    Siegfried Ansorge
    Institute of Medical Technology Magdeburg, Germany
    Z Naturforsch C 58:580-9. 2003
    ..Thus, the bee product propolis can be considered as a powerful natural anti-inflammatory medicine influencing different types of immune-responses probably via immunoregulatory T cells...
  3. ncbi Dipeptidyl peptidase IV (DP IV, CD26) and aminopeptidase N (APN, CD13) as regulators of T cell function and targets of immunotherapy in CNS inflammation
    Dirk Reinhold
    Institute of Immunology, Otto von Guericke University Magdeburg, Leipziger Str 44, 39120 Magdeburg, Germany
    Int Immunopharmacol 6:1935-42. 2006
    ....
  4. ncbi Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and aminopeptidase N (APN) families in immune functions
    Siegfried Ansorge
    IMTM GmbH, Magdeburg, Germany
    Clin Chem Lab Med 47:253-61. 2009
    ..The first active dual inhibitor, IP10.C8, has been developed by IMTM for the treatment of inflammatory skin diseases and has just entered the first phase II study...
  5. ncbi Role of dipeptidyl peptidase IV (DP IV)-like enzymes in T lymphocyte activation: investigations in DP IV/CD26-knockout mice
    Dirk Reinhold
    Institute of Molecular and Clinical Immunology, Otto von Guericke University Magdeburg, Magdeburg, Germany
    Clin Chem Lab Med 47:268-74. 2009
    ....
  6. ncbi Inhibitors of dipeptidyl peptidase IV and aminopeptidase N target major pathogenetic steps in acne initiation
    Anja Thielitz
    Department of Dermatology and Venereology, Otto von Guericke University Magdeburg, Magdeburg, Germany
    J Invest Dermatol 127:1042-51. 2007
    ....
  7. ncbi Inhibition of alanyl-aminopeptidase on CD4+CD25+ regulatory T-cells enhances expression of FoxP3 and TGF-beta1 and ameliorates acute colitis in mice
    Ute Bank
    IMTM GmbH, D 39120 Magdeburg, Germany
    Int J Mol Med 20:483-92. 2007
    ..We conclude that aminopeptidase inhibitors support the suppressive activity as well as TGF-beta1 and FoxP3 expression of natural regulatory T-cells...
  8. ncbi Triggering endogenous immunosuppressive mechanisms by combined targeting of Dipeptidyl peptidase IV (DPIV/CD26) and Aminopeptidase N (APN/ CD13)--a novel approach for the treatment of inflammatory bowel disease
    Ute Bank
    IMTM GmbH, Leipziger Str 44, 39120 Magdeburg, Germany
    Int Immunopharmacol 6:1925-34. 2006
    ..In summary our results strongly suggest that combined DPIV and APN inhibition by synthetic inhibitors represents a novel and efficient approach for the pharmacological therapy of IBD by triggering endogenous immunosuppressive mechanisms...
  9. ncbi Synergistic action of DPIV and APN in the regulation of T cell function
    Uwe Lendeckel
    Institute of Experimental Internal Medicine, Otto von Guericke University Magdeburg, Leipziger Strasse 44, D 39120 Magdeburg, Germany
    Adv Exp Med Biol 524:123-31. 2003
    ..Therefore, the simultaneous inhibition of these enzymes represents a promising strategy for the pharmacological therapy of T cell mediated diseases such as autoimmune disease, inflammation, allergy, and allograft rejection...
  10. ncbi Dual inhibition of dipeptidyl peptidase IV and aminopeptidase N suppresses inflammatory immune responses
    Dirk Reinhold
    Institute of Immunology, Otto von Guericke University Magdeburg, Leipziger Str 44, 39120 Magdeburg, Germany
    Ann N Y Acad Sci 1110:402-9. 2007
    ..This review summarizes the evidence for the role of both enzymes in T cell activation in vitro and in vivo and provides a rationale for using combined and dual peptidase inhibitors to treat autoimmune diseases like MS...
  11. ncbi Outside or inside: role of the subcellular localization of DP4-like enzymes for substrate conversion and inhibitor effects
    Ute Bank
    IMTM GmbH, Department ImmunoPharm, D 39120 Magdeburg, Germany
    Biol Chem 392:169-87. 2011
    ..In summary, in cells which do express DP4 on the surface, this archetypical member of the DP4 family is the most relevant peptidase in the regulation of cellular functions...
  12. ncbi Reduced neuronal expression of insulin-degrading enzyme in the dorsolateral prefrontal cortex of patients with haloperidol-treated, chronic schizophrenia
    Hans Gert Bernstein
    Department of Psychiatry, University of Magdeburg, Magdeburg, Germany
    J Psychiatr Res 43:1095-105. 2009
    ..Furthermore, it might contribute to the altered metabolism of certain neuropeptides (IGF-I and IGF-II, beta-endorphin), in schizophrenia...
  13. ncbi PETIR-001, a dual inhibitor of dipeptidyl peptidase IV (DP IV) and aminopeptidase N (APN), ameliorates experimental autoimmune encephalomyelitis in SJL/J mice
    Dirk Reinhold
    Institute of Molecular and Clinical Immunology, Otto von Guericke University Magdeburg, D 39120 Magdeburg, Germany
    Biol Chem 392:233-7. 2011
    ..Our results demonstrate that PETIR-001 exhibits a therapeutic effect on EAE in SJL/J mice. Thus, PETIR™ represents a novel and efficient therapeutic approach for immunotherapy of CNS inflammation...
  14. ncbi Inhibitors of dipeptidyl peptidase IV-like activity mediate antifibrotic effects in normal and keloid-derived skin fibroblasts
    Anja Thielitz
    University Clinic of Dermatology and Venereology, Otto von Guericke University, Magdeburg, Germany
    J Invest Dermatol 128:855-66. 2008
    ..Inhibition of DP IV-like enzymatic activity may therefore represent a promising therapeutic approach for the treatment of fibrotic skin disorders and keloids...
  15. ncbi Dipeptidyl peptidase IV, aminopeptidase N and DPIV/APN-like proteases in cerebral ischemia
    Peter Röhnert
    KeyNeurotek Pharmaceuticals AG, Leipziger Str 44, D 39120 Magdeburg, Germany
    J Neuroinflammation 9:44. 2012
    ..We studied the expression, localisation and activity patterns of these proteases after endothelin-induced occlusion of the middle cerebral artery in rats, a model of transient and unilateral cerebral ischemia...
  16. ncbi Inflammatory bowel diseases: multiple benefits from therapy with dipeptidyl- and alanyl-aminopeptidase inhibitors
    Ute Bank
    IMTM GmbH, Department ImmunoPharm, Magdeburg, Germany
    Front Biosci 13:3699-713. 2008
    ....
  17. ncbi Assigning the phenotype of a natural regulatory T-cell to the human T-cell line, KARPAS-299
    Carmen Wolke
    Institute of Experimental Internal Medicine, Otto-von-Guericke University, Magdeburg, Germany
    Int J Mol Med 17:275-8. 2006
    ....
  18. ncbi CD26/DP IV in T cell activation and autoimmunity
    Vera Preller
    Institute of Immunology Otto-von-Guericke University, Leipziger Str 44, D-39120 Magdeburg, Germany
    Adv Exp Med Biol 575:187-93. 2006
  19. ncbi Soluble vascular endothelial growth factor, soluble VEGF receptor Flt-1 and endothelial function in healthy smokers
    Caroline Schmidt-Lucke
    Department of Internal Medicine, Division of Cardiology, Angiology and Pneumology, Otto-von-Guericke University, Magdeburg, Germany
    Int J Cardiol 100:207-12. 2005
    ..VEGF, and not sFlt-1, may be related to the pathogenesis of endothelial dysfunction in healthy smoking individuals...
  20. ncbi Inhibition of human leukocyte function, alanyl aminopeptidase (APN, CD13) and dipeptidylpeptidase IV (DP IV, CD26) enzymatic activities by aqueous extracts of Cistus incanus L. ssp. incanus
    Uwe Lendeckel
    Institute of Experimental Internal Medicine, Center of Internal Medicine, Otto von Guericke University Magdeburg, Leipziger Str 44, D 39120 Magdeburg, Germany
    J Ethnopharmacol 79:221-7. 2002
    ..Data are presented suggesting that the antiproliferative effects of CIT extracts are due to their strong cytotoxic activity...
  21. ncbi Thiol-inducing and immunoregulatory effects of flavonoids in peripheral blood mononuclear cells from patients with end-stage diabetic nephropathy
    Jörn Dietzmann
    Division of Nephrology, Otto von Guericke University of Magdeburg, Magdeburg, Germany
    Free Radic Biol Med 33:1347-54. 2002
    ..These data provide the rational for clinical trials using flavonoids in ESDN to normalize immunoregulatory defects via restoration of the cellular thiol status...
  22. ncbi Identification of extra- and intracellular alanyl aminopeptidases as new targets to modulate keratinocyte growth and differentiation
    Anja Thielitz
    Department of Dermatology and Venereology, IMTM, Leipziger Str 44, 39120 Magdeburg, Germany
    Biochem Biophys Res Commun 321:795-801. 2004
    ..Taken together, these data suggest that targeting alanyl aminopeptidases may be beneficial for psoriasis and other inflammatory skin disorders...
  23. ncbi Extracellular cysteines define ectopeptidase (APN, CD13) expression and function
    Beate Firla
    Institute of Immunology, Otto von Guericke University of Magdeburg, Magdeburg, Germany
    Free Radic Biol Med 32:584-95. 2002
    ..This may relate to various disease processes such as inflammation or malignant transformation...
  24. ncbi Increased concentrations of transforming growth factor beta1 and beta2 in the plasma of patients with glioblastoma
    Thomas Schneider
    Department of Neurosurgery, Otto von Guericke University, Leipziger Strasse 44, D 39120, Magdeburg, Germany
    J Neurooncol 79:61-5. 2006
    ..lt;6 ng/ml clearly correlates with a longer survival time. In conclusion, this study suggests that glioblastoma does secret TGF-beta2 in vivo and that TGF-beta2 may play an important role in glioblastoma patients...
  25. ncbi Regional and cellular distribution patterns of insulin-degrading enzyme in the adult human brain and pituitary
    Hans Gert Bernstein
    HansDepartment of Psychiatry, University of Magdeburg, Leipziger Str 44, D 39120 Magdeburg, Germany
    J Chem Neuroanat 35:216-24. 2008
    ..Some immunolabeling was also present in the neurohypophysis. The putative importance of the distribution of the enzyme in brain and pituitary is discussed in relation to its main known substrates, insulin, Abeta, and beta-endorphin...
  26. ncbi Changes of plasma concentrations of soluble vascular cell adhesion molecule-1 and vascular endothelial growth factor after increased perfusion of lower extremities in humans
    Caroline Schmidt-Lucke
    Department of Internal Medicine, Division of Cardiology, Angiology and Pneumology, Otto von Guericke University, Magdeburg, Germany
    Endothelium 10:159-65. 2003
    ..Short acting suppression of VEGF and SVCAM-1 under physiological conditions may explain exercise-induced vascular protection and the lack of correlation of these cytokines with activity of atherosclerotic disease...
  27. ncbi The ectopeptidases dipeptidyl peptidase IV (DP IV) and aminopeptidase N (APN) and their related enzymes as possible targets in the treatment of skin diseases
    Anja Thielitz
    University Clinic of Dermatology and Venereology, Otto von Guericke University Magdeburg, Germany
    Front Biosci 13:2364-75. 2008
    ..Targeting enzyme activity of DP IV and APN and their related molecules might be a novel approach for the treatment of acne, psoriasis or keloids...
  28. ncbi Dipeptidylpeptidase IV (DPIV) and alanyl-aminopeptidases (AAPs) as a new target complex for treatment of autoimmune and inflammatory diseases-proof of concept in a mouse model of colitis
    Ute Bank
    IMTM 2 tto-von-Guericke-University Magdeburg, L 39120 Magdeburg, Germany
    Adv Exp Med Biol 575:143-53. 2006
  29. ncbi The role of dipeptidyl peptidase IV (DP IV) enzymatic activity in T cell activation and autoimmunity
    Dirk Reinhold
    Institute of Immunology, Otto von Gueircke University Magdeburg, Germany
    Biol Chem 383:1133-8. 2002
    ..A major focus of this review are clinical aspects of the function of CD26 on hematopoietic cells and the potential usage of synthetic DP IV inhibitors as therapeutics in inflammatory disorders...
  30. ncbi New results on the conformations of potent DP IV (CD26) inhibitors bearing the N-terminal MWP structural motif
    Carmen Mrestani-Klaus
    Department of Biochemistry/Biotechnology, Martin-Luther-University Halle-Wittenberg, Kurt-Mothes-Strsse 3, Halle, Germany
    Adv Exp Med Biol 524:65-8. 2003
  31. ncbi DP IV/CD26, APN/CD13 and related enzymes as regulators of T cell immunity: implications for experimental encephalomyelitis and multiple sclerosis
    Dirk Reinhold
    Institute of Molecular and Clinical Immunology, Otto von Guericke University Magdeburg, Germany
    Front Biosci 13:2356-63. 2008
    ..In the following, we summarize the evidence for the role of both ectoenzymes in T cell activation in vitro and in vivo and provide a rationale for the use of combined or dual ectopeptidase inhibitors to treat autoimmune diseases like MS...
  32. ncbi Dipeptidyl peptidase IV (DP IV, CD26) and aminopeptidase N (APN, CD13) as regulators of T cell function and targets of immunotherapy in CNS inflammation
    Aliza Biton
    Department of Pathology, Faculty of Medicine, Hebrew University-Hadassah Medical School, POB 12272, 91120 Jerusalem, Israel
    Adv Exp Med Biol 575:177-86. 2006
  33. ncbi TGF-beta1-mediated control of central nervous system inflammation and autoimmunity through the inhibitory receptor CD26
    Vera Preller
    Institute of Immunology, Otto von Guericke University Magdeburg, Leipziger Strasse 44, 39120 Magdeburg, Germany
    J Immunol 178:4632-40. 2007
    ..These results identify CD26/DP IV as a nonredundant inhibitory receptor controlling T cell activation and Th1-mediated autoimmunity, and may have important therapeutic implications for the treatment of autoimmune CNS disease...
  34. ncbi Altered expression of ADAMs (A Disintegrin And Metalloproteinase) in fibrillating human atria
    Marco Arndt
    Institute of Experimental Internal Medicine, University Hospital Magdeburg, Germany
    Circulation 105:720-5. 2002
    ..The purpose of the present study was to determine whether structural remodeling of the atria during atrial fibrillation (AF) is associated with altered ADAM expression...
  35. ncbi Effect of 2 anesthetic techniques on the postoperative proinflammatory and anti-inflammatory cytokine response and cellular immune function to minor surgery
    Christine E Schneemilch
    Department of Anesthesiology and Intensive Care Medicine, Otto von Guericke University, 39120 Magdeburg, Germany
    J Clin Anesth 17:517-27. 2005
    ....
  36. ncbi Calpains and cytokines in fibrillating human atria
    Andreas Goette
    Division of Cardiology, Department of Internal Medicine, University Hospital Magdeburg, 39120 Magdeburg, Germany
    Am J Physiol Heart Circ Physiol 283:H264-72. 2002
    ..In conclusion, atria of patients with permanent AF show evidence of calpain I activation that might contribute to structural remodeling and contractile dysfunction, whereas there is no evidence of activation of tissue cytokines...
  37. ncbi Pronapsin A and B gene expression in normal and malignant human lung and mononuclear blood cells
    Matthew Cook
    School of Biosciences, Cardiff University, P O Box 911, Cardiff CF10 3US, Wales, UK
    Biochim Biophys Acta 1577:10-6. 2002
    ....
  38. ncbi Transcellular proteolysis demonstrated by novel cell surface-associated substrates of dipeptidyl peptidase IV (CD26)
    Susan Lorey
    Department of Biochemistry and Biotechnology, Institute of Biochemistry, Martin Luther University Halle Wittenberg, Kurt Mothes Strasse 3, D 06120 Halle Saale, Germany
    J Biol Chem 277:33170-7. 2002
    ..These data demonstrate that ectopeptidases such as DP IV may be involved in communication between blood cells via proteolysis of cell-associated substrates...
  39. ncbi Possible role of DP IV inhibitors in acne therapy
    Anja Thielitz
    Department of Dermatology and Venereology, Otto-von-Guericke University, Leipziger Str. 44, D-39120 Magdeburg, Germany
    Adv Exp Med Biol 575:163-7. 2006
  40. ncbi Different modes of dipeptidyl peptidase IV (CD26) inhibition by oligopeptides derived from the N-terminus of HIV-1 Tat indicate at least two inhibitor binding sites
    Susan Lorey
    Department of Biochemistry Biotechnology, Institute of Biochemistry, Martin Luther University Halle Wittenberg, Halle, Germany
    Eur J Biochem 270:2147-56. 2003
    ..These findings give new insights for the development of more potent and specific peptide-based DP IV inhibitors. Such inhibitors could be useful for the treatment of autoimmune and inflammatory diseases...
  41. ncbi Dipeptidyl peptidase IV inhibitors with the N-terminal MXP sequence: structure-activity-relationships
    Jurgen Faust
    Institute of Biochemistry, Department of Biochemistry Biotechnology, Martin Luther University Halle Wittenberg, Germany
    Adv Exp Med Biol 524:175-9. 2003